Two years of instability within the mergers and acquisitions market has led to some beneficial lessons for the pharmaceutical industry. More companies are focused on spurring organic innovation with a focus on strategic partnerships with companies that will build lasting relationships over typical acquisitions. Despite the decrease in deal values in the past year, many in the life sciences industry are projecting a turnaround in growth. There are various areas garnering excitement within the industry, particularly as other market participants fight for a share of the booming glucagon-like peptide 1 (GLP-1) industry and promising developments for Alzheimer’s disease treatments.
Read the full article: Weight-Loss, Alzheimer Drugs Drive M&A Market in Life Sciences //
Source: https://news.bloomberglaw.com/us-law-week/weight-loss-alzheimer-drugs-drive-m-a-market-in-life-sciences